"Wall Street's Skyrocketing Forecasts: Anti-Obesity Drug Sales Set to Surpass $100 Billion"

Wall Street analysts are raising their forecasts for the sales of anti-obesity drugs, such as Wegovy and Mounjaro, with estimates ranging from $71 billion to $200 billion by 2035. Guggenheim analyst Seamus Fernandez believes that GLP-1-based incretins will become the most prescribed drugs ever by 2031, with potential benefits for cardiovascular health, sleep apnea, and chronic kidney disease. Citi's forecast is more conservative, assuming a smaller patient population opting for the drugs. Despite high prices and limited insurance coverage, analysts expect these issues to be resolved over time, leading to peak sales of around $100 billion by 2030. Eli Lilly, which sells Mounjaro, is expected to capture a significant portion of this market.